⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
CIPLA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.2
| Stock Code | CIPLA | Market Cap | 1,02,479 Cr. | Current Price | 1,268 ₹ | High / Low | 1,673 ₹ |
| Stock P/E | 22.4 | Book Value | 412 ₹ | Dividend Yield | 1.02 % | ROCE | 20.1 % |
| ROE | 16.0 % | Face Value | 2.00 ₹ | DMA 50 | 1,359 ₹ | DMA 200 | 1,450 ₹ |
| Chg in FII Hold | -0.61 % | Chg in DII Hold | 0.47 % | PAT Qtr | 822 Cr. | PAT Prev Qtr | 1,211 Cr. |
| RSI | 29.6 | MACD | -17.8 | Volume | 22,73,484 | Avg Vol 1Wk | 17,59,305 |
| Low price | 1,265 ₹ | High price | 1,673 ₹ | PEG Ratio | 1.22 | Debt to equity | 0.00 |
| 52w Index | 0.88 % | Qtr Profit Var | -42.9 % | EPS | 57.2 ₹ | Industry PE | 27.6 |
📊 Financial Overview
- Revenue & Profitability: Quarterly PAT fell from 1,211 Cr. to 822 Cr., showing short-term weakness. EPS at 57.2 ₹ remains strong, reflecting solid earnings capacity.
- Margins & Returns: ROE at 16.0% and ROCE at 20.1% are healthy, indicating efficient capital use.
- Debt Profile: Debt-to-equity ratio of 0.00 highlights a debt-free balance sheet, ensuring stability.
- Cash Flow: Dividend yield of 1.02% supports shareholder returns, backed by consistent profitability.
💹 Valuation Indicators
- P/E Ratio: 22.4 vs Industry PE of 27.6 → undervalued relative to peers.
- P/B Ratio: Current Price 1,268 ₹ vs Book Value 412 ₹ → P/B ~3.08, reasonable for the sector.
- PEG Ratio: 1.22 → suggests fair valuation but not deeply undervalued.
- Intrinsic Value: Appears moderately undervalued compared to industry benchmarks.
🏢 Business Model & Competitive Advantage
- Cipla operates in pharmaceuticals, focusing on generics, respiratory therapies, and specialty drugs.
- Strong brand presence and diversified product portfolio provide competitive strength.
- Debt-free structure and healthy returns enhance financial resilience.
📈 Technical & Entry Zone
- Stock trading at 1,268 ₹, below 50 DMA (1,359 ₹) and 200 DMA (1,450 ₹).
- RSI at 29.6 indicates oversold territory; MACD negative suggests short-term weakness.
- Entry Zone: Attractive between 1,240–1,270 ₹ for accumulation, with long-term holding potential.
✅ Positive
- Strong ROE (16.0%) and ROCE (20.1%).
- Near debt-free balance sheet (Debt-to-equity 0.00).
- Undervalued compared to industry PE.
⚠️ Limitation
- Quarterly PAT decline (-42.9%) shows short-term weakness.
- P/B ratio (~3.08) indicates premium valuation compared to book value.
- FII holdings decreased (-0.61%), reflecting cautious sentiment.
📉 Company Negative News
- No major recent negative news, but profit decline and reduced FII holdings raise caution.
📈 Company Positive News
- Increase in DII holdings (+0.47%) signals domestic institutional confidence.
- Strong brand presence and diversified product portfolio support long-term growth.
🏭 Industry
- Pharmaceutical sector benefits from global demand for generics and specialty drugs.
- Industry PE at 27.6 indicates high valuations across the sector.
- Competition from domestic and global pharma companies remains a challenge.
🔮 Conclusion
- CIPLA shows strong fundamentals with healthy returns, low leverage, and brand strength.
- Valuation is moderate compared to industry, though short-term profit weakness is a concern.
- Recommendation: Accumulate in the 1,240–1,270 ₹ range for long-term holding, focusing on global demand for generics and specialty therapies.